百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参

每日经济新闻08-11 07:01

丨 2026年8月11日星期二丨　　NO.1百济神州与Revolution Medicines宣布达成临床开发及区域商业化合作　　8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司Revolution Medicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。　　点评：本次合作使百济神州有机会评估公司肿瘤产品...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2658950539?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-11 07:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658950539","market":"us","top_or_hot":-1,"title":"百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参","media":"每日经济新闻","content":"<div>\n<p>丨 2026年8月11日星期二丨　　NO.1百济神州与Revolution Medicines宣布达成临床开发及区域商业化合作　　8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司Revolution Medicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。　　点评：本次合作使百济神州有机会评估公司肿瘤产品...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202608113837029212.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-11 07:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202608113837029212.html><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>丨 2026年8月11日星期二丨　　NO.1百济神州与Revolution Medicines宣布达成临床开发及区域商业化合作　　8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司Revolution Medicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。　　点评：本次合作使百济神州有机会评估公司肿瘤产品...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202608113837029212.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1588","symbol_name":"回港中概股","start_time":0,"source_url":"http://finance.eastmoney.com/a/202608113837029212.html","article_id":"2658950539","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837029212.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2658950539","pubTimestamp":1786402877,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"丨2026年8月11日星期二丨NO.1百济神州与RevolutionMedicines宣布达成临床开发及区域商业化合作8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司RevolutionMedicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","603087":"甘李药业","688235":"百济神州","BK1588":"回港中概股","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0828237510.HKD":"SCHRODER ISF BIC (BRAZ IN CH)\"A\" (HKD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0228659784.USD":"施罗德金砖四国基金","KURE":"KraneShares MSCI All China Health Care Index ETF","CANC":"TEMA ONCOLOGY ETF","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK1515":"抗疫概念","09939":"开拓药业-B","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","BK1500":"做空集合股","BK4139":"生物科技","BK1574":"生物医药B类股","BD":"Russell Investments Core Plus Bond ETF","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","BK1583":"高瓴概念","BK0239":"医药制造","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","ONC":"百济神州","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","PTH":"Invesco Dorsey Wright Healthcare Momentum ETF","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BBH":"VanEck Biotech ETF","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK4588":"碎股","IDNA":"iShares Genomics Immunology and Healthcare ETF","RVMD":"Revolution Medicines, Inc.","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK1161":"生物科技","06160":"百济神州","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC"},"translate_title":"BeiGene and Revolution Medicines Announce Collaboration; Ganli Pharmaceutical Announces New Weight Loss Drug Overseas BD | Medical Morning Ginseng","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1.5,"603087":1.5,"688235":1.5,"BD":1.5,"ONC":1.5,"06160":1.5,"KURE":0.6,"CANC":0.6,"IDNA":0.6,"RVMD":1.5,"09939":1.5,"PTH":0.6,"BBH":0.6},"content_text":"丨 2026年8月11日星期二丨　　NO.1百济神州与Revolution Medicines宣布达成临床开发及区域商业化合作　　8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司Revolution Medicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。　　点评：本次合作使百济神州有机会评估公司肿瘤产品管线中的候选药物与Revolution Medicines四款极具开发潜力的RAS(ON)抑制剂的联合治疗方案，也有助于Revolution Medicines进一步扩大创新RAS(ON)抑制剂的可及性，从而支持Revolution Medicines持续推进全球战略。　　NO.2 甘李药业与Menarini签署博凡格鲁肽项目授权许可协议　　8月10日，甘李药业宣布，公司近日与意大利制药企业美纳里尼（Menarini）达成独家许可协议，授予美纳里尼在公司自主研发的博凡格鲁肽超重或肥胖适应证项目在授权区域内的上市注册及商业化的权利。合同签署后，美纳里尼将支付不可退还的首付款6200万欧元，研发里程碑、上市里程碑及销售里程碑款项，累计最高可达6.64亿欧元。　　点评：本次合作将有助于甘李药业在授权区域建立更广泛的品牌认知和学术影响力，增强公司在GLP-1RA治疗领域的国际竞争力。预计将对公司2026年度及后续年度经营业绩产生积极影响。　　NO.3 天士力董事长由周辉变更为蔡金勇　　8月10日，天士力发布关于董事长变更的公告，因工作调整原因，周辉不再担任天士力董事长职务，但仍继续担任公司董事等职务；非独立董事蔡金勇被选举为公司第九届董事会董事长。　　点评：周辉担任董事长期间，统筹布局心血管及代谢、神经/精神、消化三个核心治疗领域，推动公司战略转型与创新发展。蔡金勇接棒后，建议投资者继续关注公司此前确立的“创新驱动，成为中国医药市场的领先企业”战略的落实情况。　　NO.4 蔡买松成为太极集团新董事长　　8月10日，太极集团发布公告，称公司董事会同意选举蔡买松为公司董事长，任期自本次董事会审议通过之日起至第十届董事会届满时止。　　点评：蔡买松兼具药学专业、医药流通、风控及行业监管复合履历，同时身兼国药体系多家企业管理职务，契合公司当下经营转型需求。本次人事调整是国药体系深化老牌中药企业改革的关键一步，短期需观察管理层落地经营改善举措。　　NO.5 百花医药5连板 公司称股价已偏离上市公司基本面　　截至8月10日，百花医药已经连续5个交易日涨停，涨幅达60.97%。公司发布股票交易异常波动公告，称公司基本面未发生重大变化，市场环境、行业政策没有发生重大调整，股价已偏离上市公司基本面。　　点评：从经营数据看，公司的一季度营收、净利润同比大幅下滑，没有新增重大利好与行业政策变动支撑估值，股价存在大幅回调隐患。公司发布异动公告客观提示估值泡沫，提醒投资者理性区分题材行情与企业真实经营情况，警惕盲目追高带来的亏损风险。（文章来源：每日经济新闻）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2658950539","isCrawlerRequest":true}